Loading company…
OnCusp Therapeutics develops oncology drugs for solid and blood cancers.
Founded in 2021 and based in New York, OnCusp Therapeutics is a biopharmaceutical company with an additional office in Shanghai. Its pipeline includes CUSP06, an antibody-drug conjugate targeting CDH6, and CUSP03 and CUSP02 for hematologic and solid tumors. In January 2024, it raised USD 100 million in Series A funding. The company plans to advance clinical proof of concept for CUSP06.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in